Graft-Versus Host Disease
Bone Marrow/Stem Cell Transplant – NCI-04-C-0281
Dr. Steven Pavletic
Principal Investigator
NCI is currently conducting the following trial for patients with chronic graft-versus-host disease (GVHD). Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Pavletic and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
- Trial participants will come to the NIH in Bethesda, MD for a comprehensive, multidisciplinary evaluation lasting 4 days
- Participants will have blood testing, organ evaluation, and comprehensive consults with multidisciplinary team members
- Recommendations will be made to participant's referring physician for GVHD treatment options
Why is this trial important?
This study will examine the natural history of chronic graft-versus-host disease, a complication of blood or bone marrow stem cell transplant treatments. Patients with cancers of the blood and immune system can sometimes benefit greatly from, and even be cured by, transplants of stem cells (cells produced by the bone marrow that mature into blood cells). In addition to producing new bone marrow and restoring normal blood production and immunity, the donated cells fight any residual tumor cells that might have remained in the body. However, donated immune system cells called T cells sometimes attack healthy tissues in a reaction called graft-versus-host-disease (GVHD). Chronic GVHD (cGVHD) is one of the most serious complications of stem cell transplants. It can affect almost any part of the body, especially the skin, mouth, liver, gut, and eyes. A better understanding of cGVHD may lead to improved treatments.
Back to Top
